Truist raises target for Exelixis stock to USD 54.00

Published on 10/08/2026 at 19:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue rose 10.60 percent to USD 628.69 million. Exelixis stock costs EUR 53.28 on October 8, 2026 after EUR 52.20.

Key points in brief

Truist raised its Exelixis target from USD 52.00 to USD 54.00 on October 7, 2026.
Second-quarter revenue reached USD 628.69 million, up 10.60 percent year over year.
The Lang & Schwarz quote was EUR 53.28 on October 8, 2026, plus 2.07 percent versus the prior close.

EXEL, US30161Q1040, Illustration mit AI erstellt.

Exelixis (ISIN US30161Q1040) is tied to a USD 54.00 Truist target, raised from USD 52.00 on October 7, 2026, according to Markets Insider. At Lang & Schwarz, the euro quote was EUR 53.28 on October 8, 2026 at 7:40 p.m. CEST, plus 2.07 percent versus the prior close.

Target cut meets a mixed quarter

Truist kept a Hold rating while lifting its target, a valuation signal that leaves the analyst view below the latest euro quote when currencies are kept separate. The broader research note cited continued commercial strength but also highlighted valuation and policy risks, according to Markets Insider on October 7, 2026.

Three dated events shape EXEL

On August 5, 2026, Exelixis reported USD 628.69 million of second-quarter revenue and USD 0.91 in earnings per share, versus USD 0.85 consensus, according to MarketBeat. On September 10, 2026, the FDA extended the zanzalintinib review by three months after updated safety and efficacy data, as MarketScreener reported. On October 7, 2026, Truist raised its target to USD 54.00 from USD 52.00.

What does the delay mean for 2027?

The revised FDA action date is March 3, 2027, according to MarketScreener. For the pipeline, the three-month extension shifts the regulatory timetable while Exelixis continues commercial execution around cabozantinib and prepares additional zanzalintinib data.

Next dates and stock context

TradingView lists November 3, 2026 as the next earnings report date. Its Nasdaq listing data show a 52-week range of USD 33.76 to USD 61.14, placing the latest primary-market quote below the yearly high while the euro quote reflects a different venue and currency.

Euro quote moves after hours

The Lang & Schwarz price was EUR 53.28 on October 8, 2026 at 7:40 p.m. CEST, up 2.07 percent from the EUR 52.20 prior close of October 7, 2026. The company had a market capitalization of USD 15.0 billion as of October 8, 2026.

The further course of trading is shown by the continuously updated real-time quote of Exelixis stock.